A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Inclusion Criteria

• •Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)
• •Measurable disease sites on CT scan (\>1.5 cm in longest dimension)
• •Adequate hematologic function:
• •1. Absolute Neutrophil Count \>1500 cells/mm3
• •2. Platelets \>50000 cells/mm3
• •3. Hemoglobin \>8.0 g/dL
• •Adequate hepatic and renal function:
• •1. AST or ALT ≤2.5 x ULN
• •2. Bilirubin ≤1.5 x ULN
• •3. Estimated creatinine clearance (Cockcroft-Gault) \>40 mL/min
• •ECOG 0 or 1